InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,675.12
(
0.64%
)
US TECH 100
19,322.00
(
0.71%
)
Dow Jones
41,841.63
(
0.85%
)
Brent Oil
70.66
(
-0.15%
)
Bitcoin
84,212.32
(
2.01%
)
Post# of 254825
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 121292
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 201835

Tuesday, 09/06/2016 9:52:03 AM

Tuesday, September 06, 2016 9:52:03 AM

Post# of 254825
CLCD +67% on positive data from phase-3 SAMURAI study of Lasmiditan in migraine:

http://finance.yahoo.com/news/colucid-pharmaceuticals-announces-achievement-both-110000423.html

Results of the second phase-3 study of Lasmiditan in migraine (SPARTAN) are due in 2H17. SPARTAN has the same design as SAMURAI except that SPARTAN added the 50mg dose and includes ex-US trial sites. Both trials have an SPA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (5) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (5) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up